Leustat

Cladribine, the active ingredient in Leustat, is a purine nucleoside analog presented as an intravenous formulation for use in the treatment of hairy cell leukemia, a rare B‑cell malignancy. It works by targeting lymphocytes and inducing apoptosis.

GNH USA supplies Leustat as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide, with adherence to stringent quality and regulatory standards.

Leustat is a purine nucleoside analog used in the management of hematologic malignancies that involve malignant B‑cells.

Hairy cell leukemia: induces remission by eliminating malignant B‑cells and restoring normal hematopoiesis.

Leustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during treatment. - Fever: transient elevations in body temperature. - Infections: increased susceptibility to bacterial or viral infections. - Lymphopenia: reduced lymphocyte counts. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Severe neutropenia: profound reduction in neutrophils, raising infection risk. - Opportunistic infections: including fungal or viral pathogens. - Secondary malignancies: rare development of new cancers. - Autoimmune hemolytic anemia: immune‑mediated destruction of red cells. - Hepatic toxicity: elevated liver enzymes or liver injury.

Prior to initiating therapy with Leustat, several safety considerations should be observed.

Monitor blood counts: perform regular CBC to detect cytopenias. Assess infection risk: screen for active infections before therapy. Evaluate renal function: adjust use if renal impairment is present. Avoid live vaccines: due to immunosuppressive effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leustat can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent chemotherapy agents: may increase myelosuppression. - Live vaccines: contraindicated during treatment. - Antiviral prophylaxis agents: may require dose adjustment.

Moderate Interactions (Monitor Closely): - CYP450 substrates: monitor plasma levels as cladribine may affect metabolism. - Immunosuppressive biologics: combined use can heighten infection risk.